Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Up 58%: Should You Buy Achillion Pharmaceuticals Today?

Investors in Achillion Pharmaceuticals  (NASDAQ: ACHN  ) got a double-whammy of good news over the last two days, with Merck's (NYSE: MRK  ) purchase of fellow hepatitis c biotech Idenix pumping shares up over 40%. And Achillion is up over 50% today on further good news -- the FDA removed an almost year-long clinical hold on its drug sovaprevir, allowing its phase 2 drug trial to continue.

Good news -- but good enough to buy Achillion? What about competitors, like Gilead's (NASDAQ: GILD  ) Sovaldi and incoming drugs from AbbVie  (NYSE: ABBV  ) , Merck, and Bristol-Myers Squibb? In the video below, health care analyst Michael Douglass lays out his thoughts on why investors would be better served staying on the sidelines.

If you think Achillion's got a great opportunity, wait till you hear about this!
Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out, and some early viewers are claiming its everyday impact could trump the iPod, iPhone, and the iPad. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!

Read/Post Comments (0) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2988885, ~/Articles/ArticleHandler.aspx, 9/4/2015 1:02:21 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Michael Douglass

As the Motley Fool's Health Care Editor/Analyst, I focus on all things health care -- although my greatest interest is in the megatrends reshaping the American health care system, including the Affordable Care Act, Accountable Care Organizations, a shifting regulatory landscape, and the new drug discoveries fundamentally changing disease management and treatment.

Today's Market

updated Moments ago Sponsored by:
DOW 16,081.60 -293.16 -1.79%
S&P 500 1,920.47 -30.66 -1.57%
NASD 4,676.95 -56.55 -1.19%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/4/2015 12:47 PM
ABBV $59.26 Down -2.33 -3.78%
AbbVie Inc. CAPS Rating: ****
ACHN $7.70 Up +0.15 +1.99%
GILD $102.07 Up +0.16 +0.16%
Gilead Sciences CAPS Rating: *****
MRK $51.33 Down -1.32 -2.51%
Merck & Co., Inc. CAPS Rating: ****